These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 37851884)

  • 1. Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin. Reply.
    Rosenstock J; Gowda A; Liang B
    N Engl J Med; 2023 Oct; 389(16):1533. PubMed ID: 37851884
    [No Abstract]   [Full Text] [Related]  

  • 2. Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin.
    Rosenstock J; Bain SC; Gowda A; Jódar E; Liang B; Lingvay I; Nishida T; Trevisan R; Mosenzon O;
    N Engl J Med; 2023 Jul; 389(4):297-308. PubMed ID: 37356066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin.
    Sugiyama K
    N Engl J Med; 2023 Oct; 389(16):1532. PubMed ID: 37851882
    [No Abstract]   [Full Text] [Related]  

  • 4. Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin.
    Misbin RI
    N Engl J Med; 2023 Oct; 389(16):1532-1533. PubMed ID: 37851883
    [No Abstract]   [Full Text] [Related]  

  • 5. Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial.
    Mathieu C; Ásbjörnsdóttir B; Bajaj HS; Lane W; Matos ALSA; Murthy S; Stachlewska K; Rosenstock J
    Lancet; 2023 Jun; 401(10392):1929-1940. PubMed ID: 37156252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Once-Weekly Insulin Icodec
    Ribeiro E Silva R; de Miranda Gauza M; Guisso MES; da Silva JON; Kohara SK
    Arch Endocrinol Metab; 2023 May; 67(5):e000614. PubMed ID: 37249450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial.
    Bajaj HS; Bergenstal RM; Christoffersen A; Davies MJ; Gowda A; Isendahl J; Lingvay I; Senior PA; Silver RJ; Trevisan R; Rosenstock J
    Diabetes Care; 2021 Jul; 44(7):1586-1594. PubMed ID: 33875485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypoglycaemia frequency and physiological response after double or triple doses of once-weekly insulin icodec vs once-daily insulin glargine U100 in type 2 diabetes: a randomised crossover trial.
    Pieber TR; Arfelt KN; Cailleteau R; Hart M; Kar S; Mursic I; Svehlikova E; Urschitz M; Haahr H
    Diabetologia; 2023 Aug; 66(8):1413-1430. PubMed ID: 37308751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment.
    Rosenstock J; Bajaj HS; Janež A; Silver R; Begtrup K; Hansen MV; Jia T; Goldenberg R;
    N Engl J Med; 2020 Nov; 383(22):2107-2116. PubMed ID: 32960514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Randomized, Open-Label Comparison of Once-Weekly Insulin Icodec Titration Strategies Versus Once-Daily Insulin Glargine U100.
    Lingvay I; Buse JB; Franek E; Hansen MV; Koefoed MM; Mathieu C; Pettus J; Stachlewska K; Rosenstock J
    Diabetes Care; 2021 Jul; 44(7):1595-1603. PubMed ID: 33875484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial.
    Wysham C; Bhargava A; Chaykin L; de la Rosa R; Handelsman Y; Troelsen LN; Kvist K; Norwood P
    JAMA; 2017 Jul; 318(1):45-56. PubMed ID: 28672317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
    Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of insulin degludec versus insulin glargine U100 in adults with type 1 and type 2 diabetes mellitus in Bulgaria.
    Russel-Szymczyk M; Valov V; Savova A; Manova M
    BMC Endocr Disord; 2019 Dec; 19(1):132. PubMed ID: 31796048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes: The SWITCH 1 Randomized Clinical Trial.
    Lane W; Bailey TS; Gerety G; Gumprecht J; Philis-Tsimikas A; Hansen CT; Nielsen TSS; Warren M; ;
    JAMA; 2017 Jul; 318(1):33-44. PubMed ID: 28672316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lower rates of hypoglycaemia in older individuals with type 2 diabetes using insulin degludec versus insulin glargine U100: Results from SWITCH 2.
    Heller SR; DeVries JH; Wysham C; Hansen CT; Hansen MV; Frier BM
    Diabetes Obes Metab; 2019 Jul; 21(7):1634-1641. PubMed ID: 30891886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term cost-effectiveness analysis shows that IDegLira is associated with improved outcomes and lower costs compared with insulin glargine U100 plus insulin aspart in the US.
    Dempsey M; Mocarski M; Langer J; Hunt B
    J Med Econ; 2018 Nov; 21(11):1110-1118. PubMed ID: 30114954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ideglira is Associated With Improved Short-Term Clinical Outcomes and Cost Savings Compared with Insulin Glargine U100 Plus Insulin Aspart in the U.S.
    Dempsey M; Mocarski M; Langer J; Hunt B
    Endocr Pract; 2018 Sep; 24(9):796-804. PubMed ID: 30308134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of insulin degludec versus insulin glargine U100 on time in range: SWITCH PRO, a crossover study of basal insulin-treated adults with type 2 diabetes and risk factors for hypoglycaemia.
    Goldenberg RM; Aroda VR; Billings LK; Christiansen ASL; Meller Donatsky A; Parvaresh Rizi E; Podgorski G; Raslova K; Klonoff DC; Bergenstal RM
    Diabetes Obes Metab; 2021 Nov; 23(11):2572-2581. PubMed ID: 34322967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-term cost-utility of degludec versus glargine U100 for patients with type 2 diabetes at high risk of hypoglycaemia and cardiovascular events: A Canadian setting (DEVOTE 9).
    Pollock RF; Heller S; Pieber TR; Woo V; Gundgaard J; Hallén N; Luckevich M; Tutkunkardas D; Zinman B;
    Diabetes Obes Metab; 2019 Jul; 21(7):1706-1714. PubMed ID: 30924579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes.
    Marso SP; McGuire DK; Zinman B; Poulter NR; Emerson SS; Pieber TR; Pratley RE; Haahr PM; Lange M; Brown-Frandsen K; Moses A; Skibsted S; Kvist K; Buse JB;
    N Engl J Med; 2017 Aug; 377(8):723-732. PubMed ID: 28605603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.